vs
ADAMAS TRUST, INC.（ADAM）与RHYTHM PHARMACEUTICALS, INC.（RYTM）财务数据对比。点击上方公司名可切换其他公司
RHYTHM PHARMACEUTICALS, INC.的季度营收约是ADAMAS TRUST, INC.的1.4倍（$60.1M vs $43.2M），ADAMAS TRUST, INC.净利率更高（124.0% vs -92.6%，领先216.6%），RHYTHM PHARMACEUTICALS, INC.同比增速更快（83.8% vs 61.6%），过去两年ADAMAS TRUST, INC.的营收复合增速更高（55.5% vs 43.8%）
Rhythm Pharmaceuticals是一家专注于罕见病领域的生物制药企业，主要开发和商业化针对罕见遗传性肥胖症的靶向疗法，覆盖POMC缺陷、LEPR缺陷、巴德-毕德氏综合征等适应症，服务北美、欧洲地区缺少有效治疗方案的患者群体。
ADAM vs RYTM — 直观对比
营收规模更大
RYTM
是对方的1.4倍
$43.2M
营收增速更快
RYTM
高出22.2%
61.6%
净利率更高
ADAM
高出216.6%
-92.6%
两年增速更快
ADAM
近两年复合增速
43.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $43.2M | $60.1M |
| 净利润 | $53.5M | $-55.6M |
| 毛利率 | — | 88.1% |
| 营业利润率 | — | -87.1% |
| 净利率 | 124.0% | -92.6% |
| 营收同比 | 61.6% | 83.8% |
| 净利润同比 | 270.5% | — |
| 每股收益（稀释后） | $0.45 | $-0.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADAMRYTM
| Q1 26 | — | $60.1M | ||
| Q4 25 | $43.2M | $57.3M | ||
| Q3 25 | $36.6M | $51.3M | ||
| Q2 25 | $36.4M | $48.5M | ||
| Q1 25 | $33.1M | $32.7M | ||
| Q4 24 | $26.7M | $41.8M | ||
| Q3 24 | $20.2M | $33.3M | ||
| Q2 24 | $19.0M | $29.1M |
净利润ADAMRYTM
| Q1 26 | — | $-55.6M | ||
| Q4 25 | $53.5M | $-47.5M | ||
| Q3 25 | $44.8M | $-52.9M | ||
| Q2 25 | $8.5M | $-46.6M | ||
| Q1 25 | $42.2M | $-49.5M | ||
| Q4 24 | $-31.4M | $-43.3M | ||
| Q3 24 | $42.8M | $-43.6M | ||
| Q2 24 | $-15.6M | $-32.3M |
毛利率ADAMRYTM
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
营业利润率ADAMRYTM
| Q1 26 | — | -87.1% | ||
| Q4 25 | — | -82.2% | ||
| Q3 25 | — | -102.6% | ||
| Q2 25 | 11.7% | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | -119.0% | -98.6% | ||
| Q3 24 | — | -132.0% | ||
| Q2 24 | -124.7% | -139.2% |
净利率ADAMRYTM
| Q1 26 | — | -92.6% | ||
| Q4 25 | 124.0% | -83.0% | ||
| Q3 25 | 122.5% | -103.1% | ||
| Q2 25 | 23.4% | -96.1% | ||
| Q1 25 | 127.4% | -151.4% | ||
| Q4 24 | -117.5% | -103.6% | ||
| Q3 24 | 211.7% | -131.2% | ||
| Q2 24 | -81.9% | -110.9% |
每股收益（稀释后）ADAMRYTM
| Q1 26 | — | $-0.83 | ||
| Q4 25 | $0.45 | $-0.73 | ||
| Q3 25 | $0.36 | $-0.82 | ||
| Q2 25 | $-0.04 | $-0.75 | ||
| Q1 25 | $0.33 | $-0.81 | ||
| Q4 24 | $-0.46 | $-0.71 | ||
| Q3 24 | $0.36 | $-0.73 | ||
| Q2 24 | $-0.29 | $-0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $210.3M | $340.6M |
| 总债务越低越好 | $735.8M | — |
| 股东权益账面价值 | $1.4B | $122.9M |
| 总资产 | $12.6B | $442.3M |
| 负债/权益比越低杠杆越低 | 0.52× | — |
8季度趋势，按日历期对齐
现金及短期投资ADAMRYTM
| Q1 26 | — | $340.6M | ||
| Q4 25 | $210.3M | $388.9M | ||
| Q3 25 | $185.3M | $416.1M | ||
| Q2 25 | $160.4M | $291.0M | ||
| Q1 25 | $177.1M | $314.5M | ||
| Q4 24 | $167.4M | $320.6M | ||
| Q3 24 | $195.1M | $298.4M | ||
| Q2 24 | $235.5M | $319.1M |
总债务ADAMRYTM
| Q1 26 | — | — | ||
| Q4 25 | $735.8M | — | ||
| Q3 25 | $766.6M | — | ||
| Q2 25 | $653.0M | — | ||
| Q1 25 | $654.4M | — | ||
| Q4 24 | $573.2M | — | ||
| Q3 24 | $699.4M | — | ||
| Q2 24 | $800.7M | — |
股东权益ADAMRYTM
| Q1 26 | — | $122.9M | ||
| Q4 25 | $1.4B | $139.1M | ||
| Q3 25 | $1.4B | $148.8M | ||
| Q2 25 | $1.4B | $-11.9M | ||
| Q1 25 | $1.4B | $18.9M | ||
| Q4 24 | $1.4B | $21.7M | ||
| Q3 24 | $1.4B | $11.2M | ||
| Q2 24 | $1.4B | $39.3M |
总资产ADAMRYTM
| Q1 26 | — | $442.3M | ||
| Q4 25 | $12.6B | $480.2M | ||
| Q3 25 | $12.4B | $506.9M | ||
| Q2 25 | $10.6B | $372.7M | ||
| Q1 25 | $10.0B | $386.7M | ||
| Q4 24 | $9.2B | $392.3M | ||
| Q3 24 | $8.9B | $363.6M | ||
| Q2 24 | $8.2B | $381.8M |
负债/权益比ADAMRYTM
| Q1 26 | — | — | ||
| Q4 25 | 0.52× | — | ||
| Q3 25 | 0.55× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.41× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.56× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $134.0M | — |
| 自由现金流经营现金流 - 资本支出 | $125.9M | — |
| 自由现金流率自由现金流/营收 | 291.6% | — |
| 资本支出强度资本支出/营收 | 18.9% | — |
| 现金转化率经营现金流/净利润 | 2.50× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ADAMRYTM
| Q1 26 | — | — | ||
| Q4 25 | $134.0M | $-25.4M | ||
| Q3 25 | $6.9M | $-26.6M | ||
| Q2 25 | $39.2M | $-23.3M | ||
| Q1 25 | $25.8M | $-40.4M | ||
| Q4 24 | $14.1M | $-18.8M | ||
| Q3 24 | $-922.0K | $-25.2M | ||
| Q2 24 | $-993.0K | $-29.1M |
自由现金流ADAMRYTM
| Q1 26 | — | — | ||
| Q4 25 | $125.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-10.6M | — | ||
| Q3 24 | $-8.6M | — | ||
| Q2 24 | $-8.6M | — |
自由现金流率ADAMRYTM
| Q1 26 | — | — | ||
| Q4 25 | 291.6% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -39.6% | — | ||
| Q3 24 | -42.3% | — | ||
| Q2 24 | -44.9% | — |
资本支出强度ADAMRYTM
| Q1 26 | — | — | ||
| Q4 25 | 18.9% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 92.3% | — | ||
| Q3 24 | 37.7% | — | ||
| Q2 24 | 39.7% | — |
现金转化率ADAMRYTM
| Q1 26 | — | — | ||
| Q4 25 | 2.50× | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 4.59× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.02× | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADAM
| Other | $19.6M | 45% |
| Constructive Loans LLC | $14.4M | 33% |
| Multifamily | $9.1M | 21% |
RYTM
暂无分部数据
